Paul D. Savage, MD
- Associate Professor, Hematology and Oncology
Paul D. Savage, MD
Research Interests
- Molecular Oncology
- Molecular Genetics
- Sarcomas
- Melanomas
- Rare Cancers
- Novel Drugs
- Education
- MD, Tufts University School of Medicine, 1981
- Board Certifications
- American Board of Internal Medicine, Internal Medicine
- Memberships
- Connective Tissue Oncology Society
- American College of Physicians
- American Society of Clinical Oncology
- American Association for Cancer Research
- American Society of Hematology
- Positions
- Associate Professor, Hematology and Oncology
- Departments and Affiliations
- Hematology and Oncology
- Comprehensive Cancer Center
Research
- Phase II Trial of Angiotensin-(1-7) for the Treatment of Patients with Metastatic Sarcoma. Savage PD, Lovato J, Brosnihan KB, Miller AA, Petty WJ. . 2016; 2016:4592768.
- Reverse translation of phase I biomarker findings links the activity of angiotensin-(1-7) to repression of hypoxia inducible factor-1a in vascular sarcomas. Petty WJ, Aklilu M, Varela VA, Lovato J, Savage PD, Miller AA. BMC Cancer. 2012 Sep; 12:404.
- Phase I study of lenalidomide in solid tumors. Miller AA, Case D, Harmon M, Savage P, Lesser G, Hurd D, Melin SA. J Thorac Oncol. 2007 May; 2(5):445-9.
- Inflammatory myofibroblastic tumor with bone marrow involvement. A case report and review of the literature. Hagenstad CT, Kilpatrick SE, Pettenati MJ, Savage PD. Arch Pathol Lab Med. 2003 Jul; 127(7):865-7.
- Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). Chen MY, Bechtold RE, Savage PD. AJR Am J Roentgenol. 2002 Oct; 179(4):1059-62.